Literature DB >> 19017179

Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation.

P Ghia1, N Chiorazzi, K Stamatopoulos.   

Abstract

Several studies suggest that immune-mediated pathways are important in the pathogenesis of chronic lymphocytic leukaemia (CLL). The in vivo accumulation of leukaemic lymphocytes is facilitated by interactions of CLL cells with other cells and soluble factors that probably occur more often within the microenvironment through classical receptor-ligand interactions. These include CD40L-CD40 and chemokine-chemokine receptor interactions as well as B cell receptor (BCR) engagement by (auto)antigens. Indeed, the categorizations of CLL patients based on immunoglobulin heavy variable (IGHV) gene mutations and structure of the clone's BCR suggest that CLL patient outcome could be a reflection of ongoing BCR signalling in the context of other co-signals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017179     DOI: 10.1111/j.1365-2796.2008.02030.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  63 in total

1.  Chronic lymphocytic leukemia--genomics lead the way.

Authors:  Daniel Mertens; Lars Bullinger; Stephan Stilgenbauer
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

Review 2.  Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

Authors:  Ying Huang; Jia-Zhu Wu; Jian-Yong Li; Wei Xu
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

Review 3.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

4.  On CK2 regulation of chronic lymphocytic leukemia cell viability.

Authors:  Leila R Martins; Paulo Lúcio; Milene C Silva; Paula Gameiro; Maria G Silva; João T Barata
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

5.  Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients.

Authors:  Eleni Arvaniti; Stavroula Ntoufa; Nikos Papakonstantinou; Tasoula Touloumenidou; Nikolaos Laoutaris; Achilles Anagnostopoulos; Klea Lamnissou; Federico Caligaris-Cappio; Kostas Stamatopoulos; Paolo Ghia; Marta Muzio; Chrysoula Belessi
Journal:  Haematologica       Date:  2011-07-12       Impact factor: 9.941

6.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

7.  Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.

Authors:  Sarah E M Herman; Rashida Z Mustafa; Jennifer A Gyamfi; Stefania Pittaluga; Stella Chang; Betty Chang; Mohammed Farooqui; Adrian Wiestner
Journal:  Blood       Date:  2014-03-21       Impact factor: 22.113

8.  The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.

Authors:  Pablo E Morande; Samanta R Zanetti; Mercedes Borge; Paula Nannini; Carolina Jancic; Raimundo F Bezares; Alicia Bitsmans; Miguel González; Andrea L Rodríguez; Carlos M Galmarini; Romina Gamberale; Mirta Giordano
Journal:  Invest New Drugs       Date:  2011-09-02       Impact factor: 3.850

9.  Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Authors:  Jonathan W Friedberg; Jeff Sharman; John Sweetenham; Patrick B Johnston; Julie M Vose; Ann Lacasce; Julia Schaefer-Cutillo; Sven De Vos; Rajni Sinha; John P Leonard; Larry D Cripe; Stephanie A Gregory; Michael P Sterba; Ann M Lowe; Ronald Levy; Margaret A Shipp
Journal:  Blood       Date:  2009-11-17       Impact factor: 22.113

10.  Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia.

Authors:  Nikos Papakonstantinou; Stavroula Ntoufa; Elisavet Chartomatsidou; Giorgio Papadopoulos; Artemis Hatzigeorgiou; Achiles Anagnostopoulos; Katerina Chlichlia; Paolo Ghia; Marta Muzio; Chrysoula Belessi; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.